Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
Seeking Alpha
|
May 16, 2023
X min read
Seeking Alpha
|
May 16, 2023
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on instagram
More like this
News
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Read Now
Press
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Read Now
News
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Forbes
Read Now
Press
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Forbes
Read Now
News
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Read Now
Press
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Read Now
